Biotech Investing BriaCell's Bria-OTS+ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
Biotech Investing BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer
BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer
pharmaceutical investing BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics to Existing Shareholders
pharmaceutical investing BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS Immunotherapy for Cancer
